Clinical Trial Detail

NCT ID NCT03070093
Title Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.
Indications

acute myeloid leukemia

Therapies

Gilteritinib

Age Groups: adult senior

Additional content available in CKB BOOST